Much of the early progress in this area has been in Duchenne muscular dystrophy (DMD) where both exon skipping and gene editing have been used to restore dystrophin production in experimental models (Amoasii et al., 2018). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.